Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Regulatory News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Second Price Monitoring Extn

17 Feb 2021 16:41

RNS Number : 4849P
MGC Pharmaceuticals Limited
17 February 2021
 

Second Price Monitoring Extension

A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes.

Following the first price monitoring extension this security would still have executed more than a pre-determined percentage above or below the price of the most recent automated execution today. London Stock Exchange electronic order book users have a final opportunity to review the prices and sizes of orders entered in this security prior to the auction execution.

The applicable percentage is set by reference to a security's Millennium Exchange sector. This is set out in the Sector Breakdown tab of the Parameters document at www.londonstockexchange.com/tradingservices

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APMGPUUCPUPGGQM

Date   Source Headline
30th Jun 20239:30 amRNSCompany Update
29th Jun 202310:22 amRNSResults of Shareholder’s General Meeting
1st Jun 20237:30 amRNSAppointment of Non-Executive Director
31st May 20237:00 amRNSFirst CannEpil® delivered to UK patients
30th May 20237:01 amRNSCorporate Update - Board and UK Adviser Changes
30th May 20237:00 amRNSDispatch of General Meeting Documents
18th May 202312:00 pmRNSDirector/PDMR Shareholding
10th May 20235:05 pmRNSDirector/PDMR Shareholding
2nd May 20237:00 amRNSMalta Production Facility Receives EU-GMP Approval
28th Apr 20237:13 amRNSMarch 2023 Quarterly Activities and Cash Flow
13th Apr 20237:00 amRNSFundraise closed raising a total of £2,090,890
11th Apr 20237:01 amRNS£1.2 million raised in a conditional Placing
11th Apr 20237:00 amRNSCannEpil® available by Named Patient Request in UK
3rd Apr 20237:00 amRNSApproval to Develop and Research with Psilocybin
21st Mar 20239:05 amRNSSecond Price Monitoring Extn
21st Mar 20239:00 amRNSPrice Monitoring Extension
21st Mar 20237:00 amRNSArtemiC Listed as OTC Drug; AMC Places US$2m order
15th Mar 20234:35 pmRNSPrice Monitoring Extension
15th Mar 20237:00 amRNSFirst patient enrolled in MGC ZAM App
8th Mar 20239:00 amRNSUS$500,000 funding received under Mercer Facility
7th Mar 20237:00 amRNSCompletion of CimetrA™ Mechanism of Action study
1st Mar 20237:02 amRNSAppointment of UK Lead Broker and Change of Co Sec
28th Feb 20239:08 amRNSHalf-year Report
10th Feb 20238:45 amRNSUpdated Investor Presentation
3rd Feb 20237:00 amRNSProvision of US$600,000 funding and change of CFO
2nd Feb 20237:00 amRNSExtension of Convertible Securities Agreements
30th Jan 20237:00 amRNSDecember 2022 Quarterly Activities and Cash Flow
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
16th Jan 20237:00 amRNSChange of Adviser – SW4 Partners
11th Jan 20239:01 amRNSChange in External Financial Auditor
10th Jan 20237:00 amRNSCompletion of CimetrA™ Pre-clinical Trial
3rd Jan 20237:00 amRNSInternal Costs Review Completed and Board Change
28th Dec 20229:10 amRNSA$800,000 funding received under Mercer Facility
8th Dec 20221:47 pmEQSMGC Pharmaceuticals delivers its largest-ever order
7th Dec 20227:00 amRNSCompletion of CimetrA Efficacy Pre-clinical Trial
5th Dec 20227:00 amRNSDelivery of US$1m order of ArtemiC to AMC Holdings
2nd Dec 20227:00 amRNSPublication of MGC Pharma Glioblastoma research
28th Nov 20227:00 amRNSResult of AGM and Investor Presentation
22nd Nov 20227:00 amRNSWebsite Update
16th Nov 20229:00 amRNSNotice of AGM
9th Nov 202210:20 amRNSApplication for Admission to Trading
31st Oct 20227:00 amRNSSeptember Quarterly Activities and Cash Flow
25th Oct 20227:00 amRNSArtemiC Support - Long COVID Clinical Study Resuls
20th Oct 20227:00 amRNSOperations Update – Major Milestones Achieved
18th Oct 20229:00 amRNS2022 AGM Notice of Meeting and Annual Report
5th Oct 20221:03 pmRNSResults of Shareholder’s General Meeting
4th Oct 20227:00 amRNSAppointment of UK Advisor and Company Update
3rd Oct 20227:00 amRNSAnnual Financial Report
28th Sep 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.